Clin2
NCT06336798Possibly a fitRecruiting

Pioglitazone for pulmonary hypertension from lung disease

Pulmonary HypertensionPulmonary Hypertension Due to Lung Diseases

Treatments studied

Part of Heart & circulation, Lungs & breathing clinical trials.

This trial tests if pioglitazone, a medicine used for diabetes, can help people with high blood pressure in their lungs caused by chronic lung disease. The goal is to see if it improves how your cells use energy.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
20 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You must have high blood pressure in your lungs (pulmonary hypertension) caused by chronic lung disease, confirmed by a heart catheter test.
  • Your pulmonary hypertension medicines must be at the same dose for at least 30 days before starting.
  • You cannot have diabetes (type 1 or type 2) now or in the past year.
  • You cannot have used pioglitazone, rosiglitazone, metformin, insulin, or other diabetes medicines in the last 90 days.
  • You cannot have a history of bladder cancer or low platelet counts (≤120).
  • You cannot currently smoke or have cystic fibrosis.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07223528Not yet recruiting· Phase 1/Phase 2
Testing telaglenastat for pulmonary hypertension

This trial tests an experimental pill (telaglenastat) for people with various types of pulmonary hypertension (PH). The goal is to see if it can improve exercise ability and heart-pumping function.

Pittsburgh, Pennsylvania
NCT07179380Recruiting· Phase 3
A study of an inhaled drug for lung disease with high blood pressure

This trial tests an inhaled medicine (TPIP) for people with both lung scarring (interstitial lung disease) and high blood pressure in the lungs (pulmonary hypertension). It aims to see if the drug helps improve exercise ability and symptoms.

Los Angeles, California
NCT07116681Not yet recruiting· Early Phase 1
Inhaled treprostinil for exercise-induced pulmonary hypertension

This trial tests whether an inhaled medication called treprostinil can improve exercise ability in people with exercise-induced pulmonary hypertension. It aims to see if the drug helps with shortness of breath during activity.

NCT07333183Recruiting· Phase 2
Mosliciguat plus treprostinil for lung disease with pulmonary hypertension

This trial tests a new medicine called mosliciguat combined with an inhaled treatment (treprostinil) for people who have both scarring lung disease (interstitial lung disease) and high blood pressure in the lungs. It aims to see if this combination can improve how well you feel and function.

Kissimmee, Florida
NCT05838287Recruiting· Phase 4
Pioglitazone for heart failure with preserved pumping in type 2 diabetes

This trial tests whether pioglitazone (a diabetes medicine) helps people who have type 2 diabetes and a specific type of heart failure where the heart pumps normally. It may improve heart failure symptoms and function in carefully selected patients.

San Antonio, Texas
NCT07481981Recruiting· Phase 3
Study of once-daily inhaled TPIP for pulmonary arterial hypertension

This trial tests an inhaled medication (TPIP) that opens blood vessels in the lungs to help you breathe easier and be more active. It is for people with PAH who are already on stable treatment and have moderate symptoms.

Santa Barbara, California

Hear when a new Pulmonary Hypertension trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.